@article{frederiksen2014lowmolecularweightheparin,
  title = {Low-Molecular-Weight-Heparin as Thromboprophylaxis: a Dosage Problem in Obese Patients},
  author = {Sven G. Frederiksen and Mikael Ekelund and Rickard Rothpfeffer and Ralph Peterli and Jan L. Hedenbro},
  year = 2014,
  url = {https://ibimapublishing.com/articles/OBES/2014/282504/},
  journal = {Journal of Research in Obesity},
  volume = 2014 (2014),
  pages = 8,
  doi = 10.5171/2014.282504,
  abstract = {Background: Prophylaxis with fixed doses of low-molecular-weight heparin (LMWH) is standard procedure to reduce the risk of venous thromboembolism after surgery. Patient studies have rarely been stratified for body weight. There is evidence to suggest that lack of sufficient levels of anti-factor Xa-activity (anti-Xa) in morbidly obese patients on LMWH. Anti-Xa is used as a measurement of antithrombotic activity. The objective of the present study was to see, for obese patients, whether body weight-adjusted dosing of enoxaparin results in anti-Xa levels comparable to those of a standard fixed dose of normal weight patients. Material and Methods: Subcutaneous injections of enoxaparin 0.3 mg/kg and 0.6 mg/kg were administered to 10 morbidly obese volunteers (median body weight 127 kg). Plasma anti-Xa was measured at defined intervals for 10 hours after injection. Reference values for anti-Xa were obtained from a former study where a fixed dose of 40 mg enoxaparin was given to subjects with different body weights. Results: Body weight dosing with 0.6 mg/kg enoxaparin yields levels of anti-Xa in the same range as in normal weight patients who receive the recommended fixed dose of 40 mg. Conclusion: Body weight-adjusted dosing may be considered in perioperative thromboprophylaxis with LMWH in obese patients.},
  keywords = {low-molecular-weight heparin, obesity, surgery, thrombosis, thromboprophylaxis},
  note = Article ID: 282504
}